LivaNova PLC (LIVN) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, LivaNova PLC's filing signal continuing negative.

LivaNova PLC is a global medical technology company focused on creating ingenious medical solutions. The company operates two primary segments: Cardiopulmonary, which designs, develops, manufactures, and sells cardiopulmonary products like heart-lung machines and oxygenators used in cardiac surgery, and Neuromodulation, which develops and markets devices for treating drug-resistant epilepsy and treatment-resistant depression, including the VNS Therapy System. LivaNova's products are sold in over 100 countries, with the U.S. accounting for 53% of its net revenue in 2025, followed by Europe at 19% and the Rest of World at 28%. The company emphasizes innovation, investing in R&D to enhance its product offerings and maintain market leadership in its specialized fields.

Revenue is driven by the sale of medical devices and related accessories within its Cardiopulmonary and Neuromodulation segments. Key drivers include demand for consumables and sales of advanced systems like the Essenz Perfusion System in Cardiopulmonary, and sales of VNS Therapy devices in Neuromodulation.